Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
A Case of Subacute Cognitive Decline in a 76-year-old Man
Neurol 87:e124-e128, MacLellan, A.,et al, 2016
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
Summary of Evidence-Based Guideline Update: Evaluation and Management of Concussion in Sports
Neurol 80:2250-2257, Giza, C.,et al, 2013
Cerebral Amyloid Angiopathy
UpToDate: May 2010, Greenberg,S.M.,et al, 2010
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Altered Brain Activation in Cognitively Intact Individuals at High Risk for Alzheimer's Disease
Neurol 53:1391-1396, Smith,C.D.,et al, 1999
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
NEJM 338:506-511, Mayeux,R.,et al, 1998
Cerebral Amyloid Angiopathy:Propsects for Clinical Diagnosis and Treatment
Neurol 52:690-694, Greenberg,S.M., 1998
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Corticobasal Degeneration:Neuropathologic and Clinical Heterogeneity
Neurol 48:959-969, Schneider,J.A.,et al, 1997
Genetic Testing for Alzheimer Disease, Practical and Ethical Issues
Arch Neurol 54:1226-1229, Roses,A.D., 1997
Apolipoprotein E Genotyping in Alzheimer's Disease
Lancet 347:1091-1095, Tanzi,R.,et al, 1996
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the e4Allele for Apolipoprotein E
NEJM 334:752-758, 7911996., Reiman,E.M.,et al, 1996
Apolipoprotein E Genotyping in the Differential Diagnosis, Not Prediction, of Alzheimer's Disease
Ann Neurol 38:6-14, Roses,A.D., 1995
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995